Bajaj Healthcare Ltd

1. Regulatory milestone: $BAJAJHCARE has become the first company in India to receive the CDSCO Subject Expert Committee (SEC) recommendation to manufacture and market Cenobamate Tablets (12.5 mg to 200 mg), a next-generation anti-seizure drug for treating partial-onset seizures in adults. This is a key step toward final regulatory approval and commercialization. 2. Business impact: The recommendation strengthens Bajaj Healthcare’s specialty CNS (Central Nervous System) portfolio and positions the company to enter the high-value epilepsy treatment market with a differentiated product, potentially boosting future formulations revenue after receiving final CDSCO approval.